vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2022-4-39-45vtio-1550Research ArticleТрансплантация сердца и вспомогательное кровообращениеHeart Transplantation and Assisted CirculationСовременный взгляд на радиационно-индуцированную кардиопатию и методы ее диагностикиCurrent view on radiation-induced heart disease and methods of its diagnosisМуратовР. М.MuratovR. M.

Москва

Moscow

sorcommn@gmail.comБабенкоС. И.BabenkoS. I.

Москва

Moscow

СоркомовМ. Н.SorkomovM. N.

Соркомов Максим Нюргустанович

121552, Москва, Рублевское шоссе, д. 135

Тел. (495) 414-78-49

Maxim Sorkomov

135, Rublevskoe Shosse, Moscow, 121552, Russian Federation

Phone: (495) 414-78-49

sorcommn@gmail.comФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии имени А.Н. Бакулева» Минздрава РоссииРоссияBakulev Scientific Center of Cardiovascular SurgeryRussian Federation2022290720222443945Copyright © Муратов Р.М., Бабенко С.И., Соркомов М.Н., 20222022Муратов Р.М., Бабенко С.И., Соркомов М.Н.Muratov R.M., Babenko S.I., Sorkomov M.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1550

В последние годы кардиологам и сердечно-сосудистым хирургам все чаще приходится сталкиваться в своей практике с радиационно-индуцированными сердечно-сосудистыми заболеваниями, которые описаны в литературе, но клинически мало изучены. Лучевая терапия широко используется при лечении многих видов рака, и несмотря на немалый риск осложнений, метод применяется примерно у 20–55% онкологических больных. Кардиотоксичность, связанная с облучением, проявляется отсроченно, обычно проходит от 10 до 30 лет после лечения. Облучение средостения значительно повышает риск развития неишемической кардиомиопатии. Обзоры по проблеме оценивают распространенность радиационно-индуцированной кардиомиопатии более чем в 10%. В связи с этим важно понимать патофизиологию радиационно-индуцированной болезни сердца, учитывать факторы риска, связанные с лучевым поражением, и своевременно диагностировать патологию.

In recent years, cardiologists and cardiovascular surgeons are increasingly encountering radiation-induced heart disease (RIHD) in their practice. This complication is described in literature but is poorly understood and clinically challenging. Radiation therapy (RT) is widely used in the treatment of many cancers. Despite the considerable risk of RT complications, it is used in 20–55% of cancer patients. Radiation-associated cardiotoxicity appears to be delayed, typically 10 to 30 years following treatment. Mediastinal irradiation significantly increases the risk of non-ischemic cardiomyopathy. Recent reviews estimate the prevalence of radiation-induced cardiomyopathy at more than 10%. Therefore, it is important to understand the pathophysiology of RIHD, consider risk factors associated with radiation injury, and detect the condition early.

опухоли средостениялучевая терапиярадиационная кардиомиопатияmediastinal tumorsradiation therapyradiation-induced cardiomyopathyReferencesCutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015; 107 (4): djv008. doi: 10.1093/jnci/djv008.Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015; 107 (4): djv008. doi: 10.1093/jnci/djv008.Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MHA, Boer JPD et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109: 1878–1886. doi: 10.1182/blood-2006-07-034405.Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MHA, Boer JPD et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109: 1878–1886. doi: 10.1182/blood-2006-07-034405.Armstrong GT, Oeffinger KC, Chen Y et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013; 31: 3673–80.Armstrong GT, Oeffinger KC, Chen Y et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013; 31: 3673–80.Quintero-Martinez JA, Cordova-Madera SN, Villarraga HR. Radiation-Induced Heart Disease. J Clin Med. 2022 Jan; 11 (1): 146. doi: 10.3390/jcm11010146.Quintero-Martinez JA, Cordova-Madera SN, Villarraga HR. Radiation-Induced Heart Disease. J Clin Med. 2022 Jan; 11 (1): 146. doi: 10.3390/jcm11010146.Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005 Sep 1; 63 (1): 214–223. doi: 10.1016/j.ijrobp.2005.01.029.Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005 Sep 1; 63 (1): 214–223. doi: 10.1016/j.ijrobp.2005.01.029.Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017; 70: 2552– 2565.Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017; 70: 2552– 2565.Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012; 20: 184–188.Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012; 20: 184–188.Boerma M, Sridharan V, Mao XW, Nelson GA, Cheema AK, Koturbash I et al. Effects of ionizing radiation on the heart. Mutat Res. 2016; 770: 319–327.Boerma M, Sridharan V, Mao XW, Nelson GA, Cheema AK, Koturbash I et al. Effects of ionizing radiation on the heart. Mutat Res. 2016; 770: 319–327.Boerma M, Kruse JJ, van Loenen M, Klein HR, Bart CI, Zurcher C et al. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol. 2004; 180: 109–116.Boerma M, Kruse JJ, van Loenen M, Klein HR, Bart CI, Zurcher C et al. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol. 2004; 180: 109–116.Yarnold J, Vozenin Brotons M-C. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010; 97 (1): 149–161. doi: 10.1016/j.radonc.2010.09.002.Yarnold J, Vozenin Brotons M-C. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010; 97 (1): 149–161. doi: 10.1016/j.radonc.2010.09.002.Taunk NK, Haffty BG, Kostis JB, Goyal S. RadiationInduced Heart Disease: Pathologic Abnormalities and Putative Mechanisms. Front Oncol. 2015; 5: 39. doi: 10.3389/fonc.2015.00039.Taunk NK, Haffty BG, Kostis JB, Goyal S. RadiationInduced Heart Disease: Pathologic Abnormalities and Putative Mechanisms. Front Oncol. 2015; 5: 39. doi: 10.3389/fonc.2015.00039.Weigel C, Schmezer P, Plass C, Popanda O. Epigenetics in radiation-induced fibrosis. Oncogene. 2014; 55 (12): 1237–1239. doi: 10.1038/onc.2014.145.Weigel C, Schmezer P, Plass C, Popanda O. Epigenetics in radiation-induced fibrosis. Oncogene. 2014; 55 (12): 1237–1239. doi: 10.1038/onc.2014.145.Van Nimwegen FA, Schaapveld M, Janus CP et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015; 175: 1007–1017.Van Nimwegen FA, Schaapveld M, Janus CP et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015; 175: 1007–1017.Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003 Aug 20; 42 (4): 743–749.Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003 Aug 20; 42 (4): 743–749.Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart study. Am J Cardiol. 1987 April 15; 59 (9): 956–960.Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart study. Am J Cardiol. 1987 April 15; 59 (9): 956–960.Fleg JL. Alterations in cardiovascular structure and function with advancing age. Am J Cardiol. 1986; 57: 33–44.Fleg JL. Alterations in cardiovascular structure and function with advancing age. Am J Cardiol. 1986; 57: 33–44.Снеговой АВ, Виценя МВ, Копп МВ, Ларионова ВБ. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Злокачественные опухоли. 2016; 4 (S2): 418–427.Snegovoy AV, Vitsenya MV, Kopp MV, Larionova VB. Prakticheskie rekomendatsii po korrektsii kardiovaskulyarnoy toksichnosti, indutsirovannoy khimioterapiey i targetnymi preparatami. Zlokachestvennye opukholi. 2016; 4 (S2): 418–427. doi: 10.18027/2224-5057-2016-4s2-418-427.Tuohinen SS, Skyttä T, Poutanen T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen PL, Raatikainen P. Radiotherapy-induced global and regional differences in earlystage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study. Int J Cardiovasc Imaging. 2017 Apr; 33 (4): 463–472. doi: 10.1007/s10554-016-1021.Tuohinen SS, Skyttä T, Poutanen T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen PL, Raatikainen P. Radiotherapy-induced global and regional differences in earlystage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study. Int J Cardiovasc Imaging. 2017 Apr; 33 (4): 463–472. doi: 10.1007/s10554-016-1021.Yu AF, Ho AY, Braunstein LZ, Thor ME, Lee Chuy K, Eaton A et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. J Am Soc Echocardiogr. 2019; 32: 521–528. doi: 10.1016/j.echo.2018.12.009.Yu AF, Ho AY, Braunstein LZ, Thor ME, Lee Chuy K, Eaton A et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. J Am Soc Echocardiogr. 2019; 32: 521–528. doi: 10.1016/j.echo.2018.12.009.Lo Q, Hee L, Batumalai V, Allman C, MacDonald P, Lonergan D et al. Strain Imaging Detects Dose-Dependent Segmental Cardiac Dysfunction in the Acute Phase After Breast Irradiation. Int J Radiat Oncol Biol Phys. 2017; 99: 182–190.Lo Q, Hee L, Batumalai V, Allman C, MacDonald P, Lonergan D et al. Strain Imaging Detects Dose-Dependent Segmental Cardiac Dysfunction in the Acute Phase After Breast Irradiation. Int J Radiat Oncol Biol Phys. 2017; 99: 182–190.Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009 Oct 6; 54 (15): 1407–1424. doi: 10.1016/j.jacc.2009.04.094.Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009 Oct 6; 54 (15): 1407–1424. doi: 10.1016/j.jacc.2009.04.094.Mavrogeni SI, Sfendouraki E, Markousis-Mavrogenis G, Rigopoulos A, Noutsias M, Kolovou G et al. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors. Heart Fail Rev. 2019 Nov; 24 (6): 977–987. doi: 10.1007/s10741-019-09805-1.Mavrogeni SI, Sfendouraki E, Markousis-Mavrogenis G, Rigopoulos A, Noutsias M, Kolovou G et al. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors. Heart Fail Rev. 2019 Nov; 24 (6): 977–987. doi: 10.1007/s10741-019-09805-1.Patil S, Pingle SR, Shalaby K, Kim AS. Mediastinal irradiation and valvular heart disease. Cardiooncology. 2022 Apr 8; 8 (1): 7.Patil S, Pingle SR, Shalaby K, Kim AS. Mediastinal irradiation and valvular heart disease. Cardiooncology. 2022 Apr 8; 8 (1): 7.Van Rijswijk JW, Farag ES, Bouten CVC, de Boer OJ, van der Wal A, de Mol BAJM, Kluin J. Fibrotic aortic valve disease after radiotherapy: an immunohistochemical study in breast cancer and lymphoma patients. Cardiovasc Pathol. 2020; 45: 107176. https://doi.org/10.1016/j.carpath.2019.107176.Van Rijswijk JW, Farag ES, Bouten CVC, de Boer OJ, van der Wal A, de Mol BAJM, Kluin J. Fibrotic aortic valve disease after radiotherapy: an immunohistochemical study in breast cancer and lymphoma patients. Cardiovasc Pathol. 2020; 45: 107176. https://doi.org/10.1016/j.carpath.2019.107176.Wu W, Masri A, Popovic ZB et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013; 127 (14): 1476–1484.Wu W, Masri A, Popovic ZB et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013; 127 (14): 1476–1484.Handa N, McGregor CGA, Danielson GK et al. Valvular heart operation in patients with previous mediastinal radiation therapy. Ann Thorac Surg. 2001; 71 (6): 1880–1884.Handa N, McGregor CGA, Danielson GK et al. Valvular heart operation in patients with previous mediastinal radiation therapy. Ann Thorac Surg. 2001; 71 (6): 1880–1884.Chang AS, Smedira NG, Chang CL, Benavides MM, Myhre U, Feng J et al. Cardiac surgery after mediastinal radiation: extent of exposure influences outcome. J Thorac Cardiovasc Surg. 2007; 133 (2): 404–413.Chang AS, Smedira NG, Chang CL, Benavides MM, Myhre U, Feng J et al. Cardiac surgery after mediastinal radiation: extent of exposure influences outcome. J Thorac Cardiovasc Surg. 2007; 133 (2): 404–413.

The authors declare that there are no conflicts of interest present.